Search Results
May 26, 2026, 11:53 ET OneR and OneOncology Partner Practice Investigators to Present 23 Abstracts at ASCO 2026
The research spans a wide range of therapeutic approaches and tumor types, including lung, breast, gastrointestinal, genitourinary, hematologic malignancies, and rare cancers. The accepted abstracts, which include poster presentations and
More news about: OneOncology, LLC.
May 26, 2026, 10:51 ET Mercy BioAnalytics to Present Data at ASCO Evaluating Clinical Performance of a Blood-Based Lung Cancer Early Detection Assay in Biospecimens from the National Lung Screening Trial
early detection lung cancer biomarkers. This work represents an important milestone in advancing blood-based approaches for lung cancer screening and lung nodule triage in elevated-risk subjects.The first study reports results from a blinded evaluation of a novel blood-based lung cancer screening
More news about: Mercy BioAnalytics
May 26, 2026, 09:00 ET Adela Highlights Progress on Multi-Cancer Early Detection Study at the 2026 ASCO Annual Meeting
cancer deaths in the United States. An additional 3,900 cancer-free control participants have been enrolled. A subset of participants with Stage I–III lung cancer will undergo additional blood draws and longitudinal follow-up, enabling training and validation of a test for MRD-based recurrence detection.Adela's
More news about: Adela
May 26, 2026, 08:59 ET Florida Cancer Specialists & Research Institute Highlights Ongoing Innovation to Expand Veteran Access to Advanced Cancer Care
180 clinical trials offered at 29 FCS clinics statewide that target the most common cancers affecting veterans—including prostate, lung, bladder, colorectal and breast cancers—FCS is helping to bring cutting-edge therapies closer to home.Through its Research Patient Navigator Program,
More news about: Florida Cancer Specialists & Research Institute
May 26, 2026, 08:30 ET Caris Life Sciences Launches Behind the Diagnosis Campaign Spotlighting Patient Lives Transformed by Caris' Comprehensive Genomic Testing
Open showed that integrating Caris GPSai into routine molecular profiling identified 123 misdiagnoses across 3,958 cases submitted as presumed primary lung squamous cell carcinoma (SCC), a misdiagnosis rate of 3.1%. The true tumor origin spanned multiple lineages, including cutaneous SCC, urothelial carcinoma,
More news about: Caris Life Sciences
May 26, 2026, 08:00 ET Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy Published at the 2026 ASCO Annual Meeting
Number: e15184Quaratusugene ozeplasmid is a gene therapy that delivers a plasmid coding for the TUSC2 tumor suppressor gene to lung cancer cells, as >80% of lung cancers have been shown to have decreased or absent TUSC2 protein. TUSC2 protein levels have not correlated with PFS, presumably because
More news about: Genprex, Inc.
May 26, 2026, 07:00 ET Adcendo ApS Announces Clinical Collaboration and Supply Agreement with MSD to Evaluate ADCE-T02 in Combination with KEYTRUDA® (Pembrolizumab) in a Phase Ib Study in Patients with Advanced Solid Tumors
outcomes for patients battling cancers where tissue factor is known to be overexpressed, such as head and neck squamous cell carcinoma, non-small cell lung cancer and cervical cancer."Under the terms of the Agreement, MSD will provide pembrolizumab to Adcendo, which will be the sponsor of the Phase
More news about: Adcendo
May 26, 2026, 07:00 ET Adcendo ApS Announces Clinical Collaboration and Supply Agreement with MSD to Evaluate ADCE-T02 in Combination with KEYTRUDA® (Pembrolizumab) in a Phase Ib Study in Patients with Advanced Solid Tumors
outcomes for patients battling cancers where tissue factor is known to be overexpressed, such as head and neck squamous cell carcinoma, non-small cell lung cancer and cervical cancer."Under the terms of the Agreement, MSD will provide pembrolizumab to Adcendo, which will be the sponsor of the Phase
More news about: Adcendo
May 26, 2026, 05:32 ET Soft Tissue Sarcoma with Lung Metastases Market Set to Expand Across the 7MM During the Forecast Period (2026-2036) with Advancing Targeted and Cellular Therapies | DelveInsight
metastatic lung nodules in selected patients. Prognosis depends on factors such as the sarcoma subtype, number and size of lung lesions, and the patient's overall health.Soft Tissue Sarcoma with Lung Metastases Epidemiology SegmentationThe soft tissue sarcoma with lung metastases
More news about: DelveInsight Business Research, LLP
May 26, 2026, 00:35 ET Over 40 Studies Featuring Akeso's Innovative Oncology Agents to Be Presented at ASCO 2026: Ivonescimab's HARMONi-6 Overall Survival Data Selected for Plenary Session
PD-1 inhibitor combined with chemotherapy in the first-line setting for advanced squamous non-small cell lung cancer (sq-NSCLC). Additional notable presentations feature ivonescimab in small-cell lung cancer (SCLC) that has progressed after first-line chemoimmunotherapy, ivonescimab plus chemotherapy in
More news about: Akeso, Inc.
May 22, 2026, 18:54 ET GOSS Investor Alert - Gossamer Bio, Inc. Stockholders with Large Losses Should Contact Robbins LLP for Information About the Securities Fraud Class Action Lawsuit
company focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension (PH) associated with interstitial lung disease.
More news about: Robbins LLP
May 22, 2026, 08:30 ET Caris Life Sciences to Present 32 Studies at ASCO 2026 Highlighting Advances in Multi-omic Biomarker Research and Real-World Evidence
Session: Lung Cancer—Non-Small Cell Metastatic. Date/Time: Sunday, May 31, 2026, 9:00 AM–12:00 PM CDT. Location: Hall A, Poster: 328.Use of LIF and LIFR expression to characterize survival and tumor microenvironment composition in lung adenocarcinoma. (Abstract 8553) Session: Lung Cancer—Non-Small
More news about: Caris Life Sciences
May 22, 2026, 08:00 ET Parker Institute for Cancer Immunotherapy Brings the Power of Its Integrated Network to ASCO 2026
TPS644).Lung & Urothelial CancersRICHIS (Jonathan Villena-Vargas, MD — Weill Cornell Medicine): A randomized multicenter Phase 2 trial of radioimmunotherapy versus chemoimmunotherapy followed by surgery for c-stage IB–III non–small cell lung cancer (Abstract
More news about: Parker Institute for Cancer Immunotherapy
May 22, 2026, 00:58 ET 2026 ASCO Abstract Highlights | Innovent Announces Preliminary PoC data of IBI363 (PD-1/IL-2α-bias bispecific fusion protein) in Combination with Chemotherapy as First-line Treatment for Advanced NSCLC, Showing Encouraging Efficacy Signals and Favorable Safety
first-in-class PD-1/IL-2α-bias bispecific fusion protein IBI363 (Takeda R&D code: TAK-928) in the first-line treatment of advanced non-small cell lung cancer (NSCLC) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. An overview of the abstract information is provided below, and
More news about: Innovent Biologics
May 21, 2026, 21:52 ET 아스트라제네카, 로슈진단 아시아태평양과 함께 유방암 및 폐암 첨단 병리학의 지속 가능한 생태계 가속화 지원
8. BioPharma Asia. 2026. Roche granted FDA Breakthrough device designation for AI-driven companion diagnostic for non-small cell lung cancer.
More news about: AstraZeneca
May 21, 2026, 20:00 ET Kelun-Biotech to Present Two Registrational Studies in the Oral Presentation Session on Non-Small Cell Lung Cancer at ASCO 2026
treatment for PD-L1 positive advanced non-small cell lung cancer (NSCLC): Results from the randomized, controlled Phase III OptiTROP-Lung05 study, to be presented as an oral presentation scheduled on May 29, 2026, 3:12 PM-3:24 PM CDT (Abstract #8506: Lung Cancer – Non-Small Cell Metastatic)A total
More news about: Kelun-Biotech
May 21, 2026, 20:00 ET 2026 ASCO | 科倫博泰2項 註冊研究入選2026 ASCO非小細胞肺癌口頭報告專場
蘆康沙妥珠單抗(sac-TMT)(佳泰萊®)聯合帕博利珠單抗(K藥)對比帕博利珠單抗一線治療PD-L1陽性晚期NSCLC：隨機、對照III期註冊研究(OptiTROP-Lung05) (摘要編號#8506)新一代選擇性RET抑制劑富馬酸侖博替尼(A400/EP0031，寧泰萊®[1])治療RET融合陽性NSCLC關鍵註冊研究 (摘要編號#8505)成都2026年5月22日
More news about: 科倫博泰
May 21, 2026, 19:49 ET 2026 ASCO Abstract Highlights: Innovent Biologics' IBI363 (PD-1/IL-2α-bias bispecific fusion protein) Demonstrates Robust Survival Benefits in Long-Term Follow-up of PoC Study in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer
PD-1/IL-2α-bias bispecific fusion protein IBI363 (Takeda R&D code: TAK-928) in the treatment of advanced immunotherapy(IO)-resistant non-small cell lung cancer (NSCLC) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. An overview of the abstract information is provided below, and
More news about: Innovent Biologics
May 21, 2026, 18:46 ET AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline
AndroMETa-Lung-713: A phase 2/3 study of telisotuzumab adizutecan (ABBV-400, Temab-A) vs standard of care (SOC) in patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC).
More news about: AbbVie
May 21, 2026, 17:34 ET Formosa Pharmaceuticals Announces Presentation of TSY-310 at the 2026 ASCO Annual Meeting
architecture, TSY-310 aims to provide a durable, "best-in-class" therapeutic option for patients with advanced solid tumors, including Non-Small Cell Lung Cancer (NSCLC).About Formosa Pharmaceuticals, Inc.: Formosa Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to
More news about: Formosa Pharmaceuticals Inc.,
May 21, 2026, 17:23 ET Nuvalent Highlights Upcoming Data Presentations for Neladalkib and Zidesamtinib at the 2026 American Society of Clinical Oncology Annual Meeting
highlighted pivotal data for neladalkib, an investigational ALK-selective inhibitor, in TKI pre-treated patients with advanced ALK-positive non-small cell lung cancer (NSCLC) from the global, single-arm ALKOVE-1 Phase 1/2 clinical trial, and preliminary data in patients with advanced ROS1-positive solid tumors
More news about: Nuvalent, Inc.
May 21, 2026, 17:17 ET Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress
that over 229,000 adults in the U.S. will be diagnosed with lung cancer in 2026. Lung cancer is the leading cause of cancer death in the U.S., with non-small cell lung cancer (NSCLC) being the most common type accounting for 77% of all lung cancer diagnoses.1 RET fusions are implicated in
More news about: Rigel Pharmaceuticals, Inc.
May 21, 2026, 17:05 ET Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload
NCT06224855) in solid tumor populations, including small-cell lung cancer (SCLC), non-small cell lung cancer (NSCLC) and neuroendocrine neoplasms. Data from DXC006 were accepted for oral
More news about: Whitehawk Therapeutics, Inc.
May 21, 2026, 17:00 ET Boehringer Ingelheim's oncology portfolio shows strong promise across multiple cancers at ASCO 2026
legs, ankles, or feetlung problems. HERNEXEOS can cause lung problems that are severe or life-threatening. Tell your healthcare provider right away if you have any new or worsening symptoms of lung problems, including trouble breathing, shortness of breath,
More news about: Boehringer Ingelheim
May 21, 2026, 17:00 ET Accent Therapeutics to Present Trial in Progress Poster for Phase 1/2 Study of ATX-295 at the 2026 American Society of Clinical Oncology Annual Meeting
exploiting a fundamental vulnerability in chromosomally instable tumors including high grade serous ovarian cancer (HGSOC) and squamous non-small cell lung cancer (sqNSCLC). ATX-295 is grounded in a strong body of preclinical evidence that continues to deepen our conviction in this program," said Jason
More news about: Accent Therapeutics